James B. Tananbaum Portfolio
Invests via Foresite Capital Management VI LLC | Managed by James B. Tananbaum
Invests via Foresite Capital Management VI LLC
Managed by James B. Tananbaum
Automatically Tracked
James B. Tananbaum Profile
Veteran life-sciences investor and founder-CEO known for building a crossover bio-focused investment platform that deploys patient capital across public and private companies.
James B. Tananbaum leads RA Capital, directing concentrated equity and venture investments in therapeutics, diagnostics and platform biotech, and serves on multiple corporate boards while positioning the firm between VC and long-only strategies to finance translational R&D and late-stage clinical value creation.
Veteran life-sciences investor and founder-CEO known for building a crossover bio-focused investment platform that deploys patient capital across public and private companies.
James B. Tananbaum leads RA Capital, directing concentrated equity and venture investments in therapeutics, diagnostics and platform biotech, and serves on multiple corporate boards while positioning the firm between VC and long-only strategies to finance translational R&D and late-stage clinical value creation.
Investment Philosophy & Strategy
Deploys patient, concentrated capital across public and private life-science companies, prioritizing therapeutics, diagnostics and platform biotech. Blends venture and crossover approaches to underwrite translational R&D and late-stage clinical value creation, favoring investments where scientific validation, regulatory path and clear clinical catalysts align. Time horizon is multi-stage and long, with active board engagement to derisk development and shape value inflection. Capital allocation emphasizes concentrated, conviction positions complemented by stage diversification and exit-ready public stakes. Risk discipline centers on technical due diligence, milestone-driven financing and portfolio sizing around asymmetric risk/reward.
Deploys patient, concentrated capital across public and private life-science companies, prioritizing therapeutics, diagnostics and platform biotech. Blends venture and crossover approaches to underwrite translational R&D and late-stage clinical value creation, favoring investments where scientific validation, regulatory path and clear clinical catalysts align. Time horizon is multi-stage and long, with active board engagement to derisk development and shape value inflection. Capital allocation emphasizes concentrated, conviction positions complemented by stage diversification and exit-ready public stakes. Risk discipline centers on technical due diligence, milestone-driven financing and portfolio sizing around asymmetric risk/reward.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
151.93%
Gain -3.22%
Monthly
4.98%
Yearly
79.41%
Drawdown
29.73%
$499.26M
Equity
Holdings
$499.26M
Investment
$261.59M
$266.59M
Profit -$11.75M
Realized
$28.92M
Unrealized
$237.67M
Dividends
$0
Goals
Avg. 100% completed goals
Yearly
Gain > 5% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
-3.22%
Profit
-$11.75M
Win %
77%
This Week
Compared To Last Week
Gain
-2.14%
Profit
-$11.14M
Win %
77%
This Month
Compared to last month
Gain
2.26%
Profit
$11.27M
Win %
77%
This Year
Compared to last year
Gain
15.52%
Profit
$63.43M
Win %
74%
CRVS Corvus Pharmaceuticals Inc.
+0.53%
+$128,186.31 
ATAI AtaiBeckley Inc.
0%
$0 
CNTA Centessa Pharmaceuticals plc American Depositary Receipt
0%
$0 
AGIO Agios Pharmaceuticals Inc.
-8.34%
-$1.43M 
DNLI Denali Therapeutics Inc.
-5.46%
-$1.61M 
VSTM Verastem Inc.
-4.92%
-$943,989.3 
OKUR OnKure Therapeutics Inc.
-4.5%
-$260,240.94 
KYMR Kymera Therapeutics Inc.
-3.37%
-$528,258.81 
CGON CG Oncology, Inc.
-2.52%
-$4.09M 
ALMS Alumis Inc.
-2.42%
-$2.97M 
ZURA Zura Bio Ltd.
-1.99%
-$49,500 
JBIO Jade Biosciences Inc.
-1.25%
-$80,000 
CLDX Celldex Therapeutics Inc.
-1.12%
-$135,842.27 
GHRS GH Research plc
-1.09%
-$97,802.52 
NERV Minerva Neurosciences Inc.
-0.99%
-$79,464 
HNGE Hinge Health Inc.
-0.53%
-$88,160 
CRNX Crinetics Pharmaceuticals Inc.
-0.13%
-$23,321.1 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 52 | Longs Won 27/52 51% | Profit Factor 6.57 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $18.47M |
| Average Win $11.15M | Best Trade (Aug 02) $94.43M | Sharpe Ratio -8.6 |
| Average Loss -$1.83M | Worst Trade (Sep 29) -$7.95M | Z-Score -0.41 (31.82%) |
| Commissions $0 | Avg. Trade Length 8m 2d | Expectancy $5.13M |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.05% | 0.52% | 3.74% | 21.18% |
| Consecutive Losing Trades | 272 | 245 | 218 | 191 | 163 | 136 | 109 | 82 | 54 | 27 |
Hover over the desired column for a detailed explanation.
Returns
Overall, MonthlyNo Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for James B. Tananbaum?
The largest contributions to the portfolio's profits come from the following stocks: Rapt Therapeutics, Inc - $35.92M, Akero Therapeutics, Inc - $7.88M, Xenon Pharmaceuticals Inc - $1.42M, Ideaya Biosciences Inc - $894,257.28, and Corvus Pharmaceuticals Inc - $822,499.86. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: Edgewise Therapeutics, Inc - $7.95M, Bicara Therapeutics Inc - $7.72M, Allogene Therapeutics Inc - $3.45M, Cullinan Therapeutics, Inc - $2.95M, and Structure Therapeutics Inc - $2.68M. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
How stable are James B. Tananbaum's monthly returns?
James B. Tananbaum's monthly returns appear quite volatile. The gap between stronger and weaker months is meaningful, which suggests that the strategy can experience noticeable swings over relatively short periods. For users assessing this profile, that usually means returns may be attractive over time, but the path can be uneven and harder to tolerate during weaker periods.
Can James B. Tananbaum's strategy be considered aggressive or moderate?
James B. Tananbaum's strategy appears moderately aggressive. The portfolio shows a clear focus on growth, with noticeable volatility and risk exposure, although not to an extreme level. This type of strategy may appeal to users seeking higher returns while accepting meaningful fluctuations along the way.
Should beginners follow James B. Tananbaum's strategy?
James B. Tananbaum's strategy is probably not ideal for beginners. The combination of risk, volatility, or portfolio complexity may make it harder to follow and understand without prior experience. Users who are new to investing may find it challenging to replicate or tolerate the performance swings.
